NEUP
Neuphoria Therapeutics Inc.
1W: +1.5%
1M: +8.0%
3M: +21.3%
YTD: +20.7%
1Y: -9.1%
3Y: -86.0%
$4.61
+0.21 (+4.77%)
After Hours: $4.50 (-0.11, -2.28%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$8.7M
52W Range3.645-21.4
Volume158,218
Avg Volume48,037
Beta0.50
Dividend—
Analyst Ratings
Company Info
CEOSpyridon Papapetropoulos
Employees8
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2021-12-16
Websiteneuphoriatx.com
100 Summit Dr
Burlington
US
Burlington
US
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Latest News
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wilson David Ian | A-Award | 8,537 | — | 2026-01-20 |
| Davies Peter Miles W | A-Award | 8,537 | — | 2026-01-20 |
| Fisher Alan | A-Award | 17,073 | — | 2026-01-20 |
| Ryan Jane | A-Award | 8,537 | — | 2026-01-20 |
| Lynx1 Capital Manage | P-Purchase | 639,110 | $5.14 | 2025-10-21 |